Heartbeam, INC

HeartBeam, Inc. has entered into an At-The-Market Equity Offering Sales Agreement with Titan Partners Securities LLC to sell up to $25 million of its common stock.

HeartBeam, Inc. is shifting to a licensing-led business model and reorganizing leadership following the departure of CEO Robert Eno.

HeartBeam, Inc. has successfully closed an underwritten public offering of 12,500,000 shares of common stock, raising $10 million in gross proceeds.

HeartBeam, Inc. received a Not Substantially Equivalent letter from the FDA for its 12-Lead ECG Synthesis Software, prompting the company to work towards a resolution while considering the launch of its 3D ECG system.

HeartBeam, Inc. announced the successful election of all nine director nominees, ratification of its independent auditor, and approval of an increase in authorized shares for its 2022 Equity Incentive Plan at its 2025 Annual Meeting.

HeartBeam, Inc. appoints CEO Robert Eno to its Board of Directors to support U.S. commercialization and growth.

HeartBeam, Inc. reports continued losses and significant cash burn, raising going concern doubts, despite FDA clearance for its HeartBeam System and progress on 12L ECG synthesis software.

HeartBeam, Inc. reported increased net losses and cash burn, raising substantial doubt about its ability to continue as a going concern, despite recent FDA clearances and successful capital raises.

HeartBeam, Inc. announces its Q1 2025 financial results, showcasing progress in FDA clearances and strategic partnerships aimed at enhancing its cardiac monitoring solutions.

HeartBeam Inc.'s Q3 2024 report reveals increased R&D spending, a net loss, and concerns about the company's ability to continue as a going concern without additional funding.

HeartBeam, Inc. reported its second quarter 2024 financial results, highlighting increased R&D spending and progress towards FDA clearance for its cardiac monitoring technology.

HeartBeam, Inc. reported its Q1 2024 financial results, highlighting increased R&D spending and progress towards FDA clearance for its AIMIGo device.

HeartBeam, Inc. reports significant progress in its 3D ECG technology with recent FDA clearances and initiates a limited market launch, despite ongoing concerns about its ability to continue as a going concern.

HeartBeam Inc. announces its 2024 financial results, highlighting FDA clearance for its HeartBeam System and continued progress in developing its ambulatory cardiac monitoring solutions.

HeartBeam Inc.'s 10-K filing details their progress in developing cardiac monitoring technology, including FDA submissions and future market strategies.

Kenneth Harry Persen, Chief Technology Officer of HeartBeam, Inc., received 105,740 shares of common stock on July 24, 2026.

Tim Cruickshank, CFO of HeartBeam, Inc., received 167,760 shares of common stock on July 24, 2026.

Branislav Vajdic, President and a Director of HeartBeam, Inc., reported multiple transactions in common stock on June 15, 2026.

Director Richard Ferrari filed an amendment to his Form 4 to correct the number of shares acquired in HeartBeam's recent public offering.

HeartBeam CFO Tim Cruickshank purchased 31,250 shares of common stock as part of the company's recent public offering.

Director Willem Elfrink acquired 187,500 shares of HeartBeam, Inc. common stock at $0.80 per share in a public offering.

HeartBeam, Inc. has announced its 2026 Annual Meeting of Shareholders, scheduled for July 31, 2026, to elect directors, ratify auditors, and approve an amendment to increase its 2022 Equity Incentive Plan shares.

HeartBeam, Inc. has scheduled its 2025 Annual Meeting of Shareholders for July 11, 2025, where key proposals include the election of nine directors, the ratification of CBIZ CPAs as independent auditor, and a substantial amendment to increase authorized shares under the 2022 Equity Incentive Plan by 3,000,000 shares.

HeartBeam, Inc. is holding its 2024 Annual Meeting of Shareholders to elect directors, approve the appointment of Marcum LLP as its independent auditor, and amend its equity incentive plan to increase authorized shares.